Lactate Dehydrogenase-to-Albumin Ratio and Adverse Outcomes in Heart Failure Patients

A retrospective cohort of 1,084 hospitalized patients with heart failure with reduced or mildly reduced ejection fraction, with a mean follow-up of 29.3 months. The dataset, authored by Yaping Zhang and last updated in April 2026, investigates the association between the lactate dehydrogenase-to-albumin ratio (LAR) and adverse clinical outcomes.

Use Cases

• Predicting heart failure-related readmission risk based on the lactate dehydrogenase-to-albumin ratio.
• Modeling all-cause mortality risk in heart failure patients using biomarker ratios.
• Assessing the incremental predictive value of a biomarker for composite clinical endpoints.
• Conducting sensitivity and subgroup analyses to evaluate the robustness of clinical findings.

Strengths

• Includes 1,084 patient records from a defined clinical cohort.
• Follow-up period of 29.3 months provides longitudinal outcome data.
• Analysis includes multiple statistical methods (Cox regression, Kaplan-Meier, Fine-Grey model) as described.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The dataset is very small at 14.5 KB, indicating limited scope.
• Data may reflect the specific biases of the single-source, single-center retrospective study.

Provenance

Source

figshare, author Yaping Zhang.

Collection Method

Retrospective cohort study of hospitalized patients.

Time Range

Mean follow-up of 29.3 months; specific collection dates are not provided.

Freshness

Last updated 2026-04-27 10:39:32; freshness should be verified.